References
- Alvarez-Erviti L, Seow Y, Yin H, et al.. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29(4):341–12.
- Hung ME, Leonard JN. Stabilization of exosome-targeting peptides via engineered glycosylation. J Biol Chem. 2015;290(13):8166–8172.
- Endo Y, Furuta A, Nishino I. Danon disease: a phenotypic expression of LAMP-2 deficiency. Acta Neuropathol. 2015;129(3):391–398.
- Woodhoo A, Iruarrizaga-Lejarreta M, Beraza N, et al.. Human antigen R contributes to hepatic stellate cell activation and liver fibrosis. Hepatology. 2012;56(5):1870–1882.
- Corso G, Heusermann W, Trojer D, et al.. Systematic characterization of extracellular vesicle sorting domains and quantification at the single molecule – single vesicle level by fluorescence correlation spectroscopy and single particle imaging. J Extracell Vesicles. 2019;8(1):1663043.
- Squadrito ML, Etzrodt M, De Palma M, et al.. MicroRNA-mediated control of macrophages and its implications for cancer. Trends Immunol. 2013;34(7):350–359.
- Kooijmans SAA, Stremersch S, Braeckmans K, et al.. Electroporation-induced siRNA precipitation obscures the efficiency of siRNA loading into extracellular vesicles. J Control Release. 2013;172(1):229–238.
- Blaya D, Aguilar-Bravo B, Hao F, et al.. Expression of microRNA-155 in inflammatory cells modulates liver injury. Hepatology. 2018;68(2):691–706.
- Bala S, Csak T, Saha B, et al.. The pro-inflammatory effects of miR-155 promote liver fibrosis and alcohol-induced steatohepatitis. J Hepatol. 2016;64(6):1378–1387.
- Csak T, Bala S, Lippai D, et al.. MicroRNA-155 deficiency attenuates liver steatosis and fibrosis without reducing inflammation in a mouse model of steatohepatitis. PLoS One. 2015;10(6):e0129251.
- Tang R, Kim CS, Solfiell DJ, et al.. Direct delivery of functional proteins and enzymes to the cytosol using nanoparticle-stabilized nanocapsules. ACS Nano. 2013;7(8):6667–6673.
- Conlan RS, Pisano S, Oliveira MI, et al.. Exosomes as reconfigurable therapeutic systems. Trends Mol Med. 2017;23(7):636–650.
- Ohno S-I, Takanashi M, Sudo K, et al.. Systemically injected exosomes targeted to EGFR deliver antitumor MicroRNA to breast cancer cells. Mol Ther. 2013;21(1):185–191.
- Tian Y, Li S, Song J, et al.. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials. 2014;35(7):2383–2390.
- Turturici G, Tinnirello R, Sconzo G, et al.. Extracellular membrane vesicles as a mechanism of cell-to-cell communication: advantages and disadvantages. Am J Physiol Cell Physiol. 2014;306(7):C621–33.
- McKelvey KJ, Powell KL, Ashton AW, et al. Exosomes: mechanisms of uptake. J Circ Biomark. 2015;4(7). doi: 10.5772/61186. eCollection.
- Cheng X-T, Xie Y-X, Zhou B, et al.. Revisiting LAMP1 as a marker for degradative autophagy-lysosomal organelles in the nervous system. Autophagy. 2018;14(8):1472–1474.
- Zagrovic B. Of RNA-binding proteins and their targets: interaction determines expression. Genome Biol. 2014;15(1):102.
- Lukong KE, Chang K-W, Khandjian EW, et al.. RNA-binding proteins in human genetic disease. Trends Genet. 2008;24(8):416–425.
- Stellos K, Gatsiou A, Stamatelopoulos K, et al.. Adenosine-to-inosine RNA editing controls cathepsin S expression in atherosclerosis by enabling HuR-mediated post-transcriptional regulation. Nat Med. 2016;22(10):1140–1150.
- Yashiro T, Nanmoku M, Shimizu M, et al.. 5-Aminoimidazole-4-carboxamide ribonucleoside stabilizes low density lipoprotein receptor mRNA in hepatocytes via ERK-dependent HuR binding to an AU-rich element. Atherosclerosis. 2013;226(1):95–101.
- Gu L, Wang H, Wang J, et al.. Reconstitution of HuR-inhibited CUGBP1 expression protects cardiomyocytes from acute myocardial infarction-induced injury. Antioxid Redox Signal. 2017;27(14):1013–1026.
- Shang J, Zhao Z. Emerging role of HuR in inflammatory response in kidney diseases. Acta Biochim Biophys Sin (Shanghai). 2017;49(9):753–763.
- Toyota K, Murakami Y, Kondo N, et al.. Cytoplasmic Hu-Antigen R (HuR) expression is associated with poor survival in patients with surgically resected cholangiocarcinoma treated with adjuvant gemcitabine-based chemotherapy. Ann Surg Oncol. 2018;25(5):1202–1210.